# CVS HEALTH Corp (CVS)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/cvs-health-corp/ JSON: https://steadybase.io/company/cvs-health-corp.json Checked Nov 10, 2026. Latest filing read: Nov 4, 2026.

## Company

- Legal name: CVS HEALTH Corp
- Ticker: CVS (NYSE)
- SEC CIK: 0000064803
- Industry: Retail-Drug Stores and Proprietary Stores (SIC 5912)
- Headquarters: Woonsocket, RI
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: cvshealth.com
- Investor relations: https://investors.cvshealth.com/?cid=site-CVSHealth:SuperNav:investors:na
- LinkedIn: https://www.linkedin.com/company/cvshealth
- Next earnings date: Feb 3, 2027 (estimated from past 8-K timing)

## Key facts

- Revenue: $402.1B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/0000064803-26-000010-index.html
- Operating income: $4.7B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/0000064803-26-000010-index.html
- Net income: $1.8B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/0000064803-26-000010-index.html
- Employees: 300,000 as of Feb 10, 2026, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/0000064803-26-000010-index.html
- Shares outstanding: 1,279,474,188 as of Oct 28, 2026 (10-Q filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/64803/000006480326000108/0000064803-26-000108-index.html
- Auditor: Ernst & Young LLP, Boston, Massachusetts, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/cvs-20251231.htm

## Business

CVS Health Corporation, together with its subsidiaries (collectively, “CVS Health,” the “Company,” “we,” “our” or “us”), is a leading health solutions company building a world of health around every consumer it serves and connecting care so that it works for people wherever they are. As of December 31, 2025, we had approximately 9,000 retail locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 87 million plan members and expanding specialty pharmacy solutions.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/cvs-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income |
|---|---|---|---|
| Dec 31, 2025 | $402.1B | $4.7B | $1.8B |
| Dec 31, 2024 | $372.8B | $8.5B | $4.6B |
| Dec 31, 2023 | $357.8B | $13.7B | $8.3B |
| Dec 31, 2022 | $322.5B | $8.0B | $4.3B |
| Dec 31, 2021 | $292.1B | $13.3B | $8.0B |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/cvs-health-corp.json

## Officers and directors

- J. David Joyner, President, CEO and Chair. LinkedIn: https://linkedin.com/in/jdjoyner. Source: Form 4 filed Apr 2, 2026, https://www.sec.gov/Archives/edgar/data/64803/000006480326000038/0000064803-26-000038-index.htm
- Brian Newman, EVP, Chief Financial Officer. LinkedIn: https://www.linkedin.com/in/briannewmancvsh. Source: Form 4 filed Jun 1, 2026, https://www.sec.gov/Archives/edgar/data/64803/000006480326000088/0000064803-26-000088-index.htm
- Brian O. Newman, Executive Vice President and Chief Financial Officer. LinkedIn: https://www.linkedin.com/in/briannewmancvsh. Source: 10-K filed Feb 10, 2026, https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/cvs-20251231.htm
- James David Clark, SVP, Cont & Chief Acct Officer. Source: Form 4 filed Jun 29, 2026, https://www.sec.gov/Archives/edgar/data/64803/000006480326000092/0000064803-26-000092-index.htm
- Amy Compton-Phillips, EVP, Chief Medical Officer. LinkedIn: https://linkedin.com/in/amycomptonphillips. Source: Form 4 filed Jun 1, 2026, https://www.sec.gov/Archives/edgar/data/64803/000006480326000086/0000064803-26-000086-index.htm
- Tilak Mandadi, EVP, Chief Exp & Tech Officer. LinkedIn: https://linkedin.com/in/tilakmandadi. Source: Form 4 filed May 11, 2026, https://www.sec.gov/Archives/edgar/data/64803/000006480326000056/0000064803-26-000056-index.htm
- Heidi B. Capozzi, EVP and Chief People Officer. LinkedIn: https://linkedin.com/in/heidi-capozzi. Source: Form 4 filed Apr 2, 2026, https://www.sec.gov/Archives/edgar/data/64803/000006480326000035/0000064803-26-000035-index.htm
- Prem S. Shah, EVP and Group President. Source: Form 4 filed Apr 2, 2026, https://www.sec.gov/Archives/edgar/data/64803/000006480326000043/0000064803-26-000043-index.htm
- Samrat S. Khichi, EVP, CPO and General Counsel. Source: Form 4 filed Apr 2, 2026, https://www.sec.gov/Archives/edgar/data/64803/000006480326000039/0000064803-26-000039-index.htm
- Steven H. Nelson, EVP and President, Aetna. Source: Form 4 filed Apr 2, 2026, https://www.sec.gov/Archives/edgar/data/64803/000006480326000041/0000064803-26-000041-index.htm
- Amy Compton-Philips, Executive Vice President and Chief Medical Officer. Source: 10-K filed Feb 10, 2026, https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/cvs-20251231.htm
- James D. Clark, Senior Vice President, Controller and Chief Accounting Officer. Source: 10-K filed Feb 10, 2026, https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/cvs-20251231.htm
- Teresa Heitsenrether, Board. Source: 8-K filed Aug 17, 2026, https://www.sec.gov/Archives/edgar/data/64803/000119312526354096/d129035d8k.htm
- David Brown, Board member (per proxy). Source: DEF 14A filed Apr 3, 2026, https://www.sec.gov/Archives/edgar/data/64803/000130817926000201/cvs014969-def14a.htm
- John E. Gallina, Board member (per proxy). Source: DEF 14A filed Apr 3, 2026, https://www.sec.gov/Archives/edgar/data/64803/000130817926000201/cvs014969-def14a.htm
- Michael F. Mahoney, Board member (per proxy). Source: DEF 14A filed Apr 3, 2026, https://www.sec.gov/Archives/edgar/data/64803/000130817926000201/cvs014969-def14a.htm
- Thomas F. Cowhey, Named in proxy. Source: DEF 14A filed Apr 3, 2026, https://www.sec.gov/Archives/edgar/data/64803/000130817926000201/cvs014969-def14a.htm

## Recent 8-K events

- Nov 4, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/64803/000119312526446150/d148827d8k.htm
- Nov 4, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/64803/000006480326000107/cvs-20261104.htm
- Aug 17, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/64803/000119312526354096/d129035d8k.htm
- Aug 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/64803/000006480326000097/cvs-20260805.htm
- May 18, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/64803/000006480326000082/cvs-20260514.htm
- May 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/64803/000006480326000051/cvs-20260506.htm
- Mar 19, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/64803/000006480326000017/cvs-20260318.htm
- Feb 10, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/64803/000006480326000009/cvs-20260210.htm
- Dec 9, 2025: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/64803/000006480325000082/cvs-20251209.htm
- Nov 20, 2025: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/64803/000119312525289805/d172430d8k.htm

## Insider trades (Form 4)

- Nov 6, 2026: Prem S. Shah (EVP and Group President) bought 23,855 shares, about $2.0M. Source: https://www.sec.gov/Archives/edgar/data/64803/000006480326000112/0000064803-26-000112-index.htm
- May 21, 2026: Larry Robbins (Director) sold 3,372,000 shares, about $317.5M. Source: https://www.sec.gov/Archives/edgar/data/64803/000090514826002617/0000905148-26-002617-index.htm
- May 8, 2026: Tilak Mandadi (EVP, Chief Exp & Tech Officer) sold 69,551 shares, about $6.2M. Source: https://www.sec.gov/Archives/edgar/data/64803/000006480326000056/0000064803-26-000056-index.htm
- Aug 20, 2025: Anne A. Finucane (Director) sold 7,500 shares, about $532,650. Source: https://www.sec.gov/Archives/edgar/data/64803/000112760225021034/0001127602-25-021034-index.htm
- Jan 23, 2025: Steven H. Nelson (EVP and President, Aetna) bought 24 shares, about $1,289. Source: https://www.sec.gov/Archives/edgar/data/64803/000006480326000004/0000064803-26-000004-index.htm

## Latest filings

- 8-K filed Aug 17, 2026: https://www.sec.gov/Archives/edgar/data/64803/000119312526354096/d129035d8k.htm
- 10-K filed Feb 10, 2026: https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/cvs-20251231.htm
- 10-Q filed Aug 5, 2026: https://www.sec.gov/Archives/edgar/data/64803/000006480326000098/cvs-20260630.htm
- DEF 14A filed Apr 3, 2026: https://www.sec.gov/Archives/edgar/data/64803/000130817926000201/cvs014969-def14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/